The financing provides substantial runway through 2028, reducing near-term dilution risk, but the sharply higher losses may concern investors. Upcoming clinical readouts from the RESOLVE trial could serve as key catalysts; traders should monitor for data releases and potential partnership interest.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals reported its Q4 2025 financial results, posting a wider net loss of $16.7 million compared to $7.5 million in the same quarter last year, driven by increased R&D and administrative costs. The company bolstered its cash position to $80.5 million through a $63.2 million public offering, extending its cash runway into the second half of 2028, while advancing its lead candidate EP-104GI with positive clinical data from the RESOLVE trial in eosinophilic esophagitis.
Key Financial Metrics
Key Facts
- Net loss increased to $16.7M in Q4 2025 from $7.5M in Q4 2024 due to higher R&D and G&A expenses.
- Cash balance rose to $80.5M as of December 31, 2025, up from $33.1M in Q4 2024.
- Raised $63.2M gross proceeds from a public offering in February 2026, including issuance of common shares and pre-funded warrants.
- Positive 52-week follow-up and tissue health data from the ongoing RESOLVE trial for EP-104GI in eosinophilic esophagitis.
- Cash runway now extends into the second half of 2028, funded by existing cash and anticipated warrant exercises.
Financial Impact
Increased quarterly net loss by $9.2M YoY; cash position increased by $47.4M YoY to $80.5M; $63.2M raised in financing.
Risk Factors
- Increasing operating losses raise concerns about path to profitability.
- Clinical trial results may not translate into regulatory approval or commercial success.
- Dependence on third-party manufacturers and potential tariff impacts on U.S.-based production.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255235 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.87 (−9.49%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.87 (+1.48%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.87 (−7.91%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.87 (−24.51%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.87 (−24.51%) |
Aug 25, 2026 8w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.87 (+7.41%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.87 (+3.00%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.87 (+6.02%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.87 (+5.37%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.87 (+3.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers